SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation Y93H

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 6 clinical trials

Clinical Trials


1 Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, With or Without BMS-791325, in Subjects Coinfected With HIV-HCV

Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 180 million people infected worldwide. In the United States an estimated 4.1 million people are infected and HCV is the principal cause of death from liver disease and leading indication for liver transplantation. Within HIV/HCV co-infected patients, liver disease due to Hepatitis C progresses even more rapidly. While combination of ribavirin (RBV) and pegylated interferon (PEG) in combination with boceprevir/telaprevir is the currently recommended therapy for chronic HCV infection and has superior cure rates compared to PEG+RBV alone in HCV monoinfected patients, treatment is still associated with a high incidence of adverse events (AEs), discontinuations and poor cure rates in several populations. Within the HIV/HCV co-infected population treatment for HCV remains complicated given drug interactions between anti-retrovirals and HCV protease inhibitors, in addition to the extensive side-effects due to PEG +RBV alone. Recent studies have demonstrated that the use of a combination of anti-virals which target HCV without interferon (IFN) can cure HCV, without additional toxicities. These novel therapies that do not rely on an IFN backbone may additionally enhance cure rates in HIV/HCV co-infected, a population which has historically been difficult to cure. The findings from this study will aid in the understanding of antiviral and host responses and determinants of response to an IFN free regimen in HIV/HCV co-infected patients.

NCT02124044 HIV-HCV Drug: Asunaprevir and Daclatasvir Drug: Asunaprevir and Daclatasvir with BMS-791325

Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson s disease, alfa-1 antitrypsin deficiency, cholangitis) 2. Positive nucleotide sequence analyses of the NS5A gene for Y93H or L31M/V polymorphisms for the 2DAA arm only. --- Y93H ---

Primary Outcomes

Description: The primary outcome was the percentage of patients with sustained viral response measured 12 weeks after the stop of treatment. The viral response was assessed by serum HCV RNA concentrations lower than 43 IU/mL - the lower limit of quantification.

Measure: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs

Time: 12 weeks after stop of treatment

2 A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects

The purpose of this study is to determine the efficacy of a 12- or 24-week treatment regimen of simeprevir in combination with daclatasvir, as measured by sustain virologic response 12 (SVR12), in treatment-naive, chronic hepatitis C virus (HCV) genotype 1b-infected participants who have advanced fibrosis or compensated cirrhosis (METAVIR F3/F4).

NCT02268864 Hepatitis C, Chronic Drug: Simeprevir Drug: Daclatasvir
MeSH:Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis
HPO:Hepatitis

For cirrhotic participants (METAVIR score F4) a biopsy performed at any previous time is acceptable - Participants who have cirrhosis must have an hepatic imaging procedure (ultrasound, computed tomography [CT] scan or magnetic resonance imaging [MRI]) within 6 months prior to the Screening visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma - Participant must have a body mass index (BMI) >= 18 Kilogram per meter^2 (kg/m^2) - Participant must be treatment naive (that is, have not received prior treatment for HCV with any approved or investigational drug) Exclusion Criteria: - Participant has co-infection with HCV of another genotype; a) Participant who has HCV genotype 1b has coinfection with HCV of a genotype other than genotype 1b - Chronic HCV genotype 1b-infected participant who has the presence of genetic variants coding for the NS5A-Y93H and/or L31M/V amino acid substitutions at Screening - Participant has evidence of current or previous episodes of hepatic decompensation (including controlled or uncontrolled ascites, bleeding varices or hepatic encephalopathy) - Participant has chronic liver disease of a non-HCV etiology (including but not limited to hemochromatosis, Wilson's disease, alfa 1-antitrypsin deficiency, cholangitis, drug- or alcohol-related liver disease, primary biliary cirrhosis) - Participant has any other uncontrolled clinically significant disease or clinically significant findings during Screening that in the opinion of the investigator could compromise the participants' safety or could interfere with the participant participating in and completing the study - Participant has coinfection with hepatitis A or hepatitis B virus (hepatitis A antibody immunoglobulin M [IgM] or hepatitis B surface antigen [HBsAg] positive at Screening) - Participant has received a solid organ transplant Inclusion Criteria: - Participant must have chronic Hepatitis C virus (HCV) genotype 1b infection confirmed at Screening - Participant must have HCV ribonucleic acid (RNA) greater than (>) 10,000 international unit per milliliter (IU/mL) at Screening - Participant must have documented fibrosis stage at Screening (or between Screening and Day 1 [baseline]). --- Y93H ---

For cirrhotic participants (METAVIR score F4) a biopsy performed at any previous time is acceptable - Participants who have cirrhosis must have an hepatic imaging procedure (ultrasound, computed tomography [CT] scan or magnetic resonance imaging [MRI]) within 6 months prior to the Screening visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma - Participant must have a body mass index (BMI) >= 18 Kilogram per meter^2 (kg/m^2) - Participant must be treatment naive (that is, have not received prior treatment for HCV with any approved or investigational drug) Exclusion Criteria: - Participant has co-infection with HCV of another genotype; a) Participant who has HCV genotype 1b has coinfection with HCV of a genotype other than genotype 1b - Chronic HCV genotype 1b-infected participant who has the presence of genetic variants coding for the NS5A-Y93H and/or L31M/V amino acid substitutions at Screening - Participant has evidence of current or previous episodes of hepatic decompensation (including controlled or uncontrolled ascites, bleeding varices or hepatic encephalopathy) - Participant has chronic liver disease of a non-HCV etiology (including but not limited to hemochromatosis, Wilson's disease, alfa 1-antitrypsin deficiency, cholangitis, drug- or alcohol-related liver disease, primary biliary cirrhosis) - Participant has any other uncontrolled clinically significant disease or clinically significant findings during Screening that in the opinion of the investigator could compromise the participants' safety or could interfere with the participant participating in and completing the study - Participant has coinfection with hepatitis A or hepatitis B virus (hepatitis A antibody immunoglobulin M [IgM] or hepatitis B surface antigen [HBsAg] positive at Screening) - Participant has received a solid organ transplant Hepatitis C, Chronic Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis This is an open-label (all people know which treatment the participants receive) study to investigate the efficacy, safety and tolerability of simeprevir and daclatasvir in chronic Hepatitis (inflammation of the liver) C virus (HCV) genotype 1b infected participants who are treatment-naive. --- Y93H ---

Primary Outcomes

Description: Participants were considered to have reached SVR12, if 12 weeks after the actual end of treatment (EOT), hepatitis C virus (HCV) ribonucleic acid (RNA) was less than lower limit of quantification ( Measure: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)

Time: At 12 weeks after end of treatment

Secondary Outcomes

Description: Participants were considered to have reached SVR4, if 4 weeks after the actual EOT, HCV RNA was Measure: Percentage of Participants With Sustained Virologic Response 4 Weeks After End of Study Drug Treatment (SVR4)

Time: At 4 weeks after actual EOT

Description: Participants were considered to have reached SVR24, if 24 weeks after the actual EOT, HCV RNA was Measure: Percentage of Participants With SVR 24 Weeks After End of Study Drug Treatment (SVR 24)

Time: At 24 weeks after actual EOT

Description: Participants were considered on-treatment failures if they did not achieve SVR12 and had (confirmed) detectable HCV RNA, ie, =) LLOQ at EOT.

Measure: Percentage of Participants With On-treatment Failure

Time: Up to Week 24 after actual EOT

Description: Participants were considered to have had viral breakthrough if they had a confirmed greater than (>) 1.0 log10 international units/milliliter (IU/mL) increase in HCV RNA from nadir OR confirmed HCV RNA >100 IU/mL while previously having achieved HCV RNA Measure: Number of Participants With Viral Breakthrough

Time: Up to Week 24

Description: Participants were considered to have had viral relapse if they did not achieve SVR12 and met the following conditions: had HCV RNA =LLOQ during the follow-up period.

Measure: Number of Participants With Viral Relapse

Time: Up to Week 24 after actual EOT

3 The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Safety and Efficacy of DAAs (Daclatasvir+Asunaprevir) in patients with chronic hepatitis C and chronic renal failure will be assessed.

NCT02580474 Hepatitis C Drug: Daclatasvir plus Asunaprevir
MeSH:Hepatitis C Renal Insufficiency Kidney Failure, Chronic
HPO:Renal insufficiency

Last dose in this previous HCV treatment course should have occurred at least 2 months prior to screening - No baseline mutation NS5A polymorphism including L31F/I/M/V and Y93H Exclusion Criteria: - A patient who having received Daclatasvir or Asunaprevir - Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study - Evidence of a medical condition contributing to chronic liver disease other than HCV or seropositive for HIV - Diagnosed or suspected hepatocellular carcinoma or other malignancies - Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage) - Received solid organ or bone marrow transplant - Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance - Significant renal, cardiovascular, pulmonary, or neurological disease and uncontrolled diabetes or hypertension in the opinion of the investigator - Known hypersensitivity to study drugs, metabolites, or formulation excipients - Who has taken investigational drugs within 2 months. --- L31F --- --- Y93H ---

Primary Outcomes

Measure: the proportion of subjects with plasma HCV RNA levels below 15 IU/mL at Week 12 After End of Treatment

Time: 36 Week

Secondary Outcomes

Measure: To evaluate the percentage of subjects with Sustained Virologic Response at Week 12 After End of Treatment

Time: 36 Week

Measure: Percentage of subjects with ALT normalization at each visit from the baseline

Time: 4, 12, 24, 36 week

Measure: Change in HCV RNA at each visit from the baseline

Time: 4, 12, 24, 36 week

Measure: Percentage of subjects who experience viral breakthrough at each visit from the baseline

Time: 4, 12, 24, 36 week

Measure: Percentage of subjects who shows Tolerability of Daclatasvir and Asunaprevir at each visit from

Time: 4, 12, 24, 36 week

4 An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R)

The purpose of this multicenter, single-arm, combination-drug study, which includes 12 weeks of treatment and 24 weeks of follow-up, is to evaluate the safety, efficacy and pharmacokinetics of ombitasvir/paritaprevir/ritonavir in Japanese adults infected with HCV GT1b, who are treatment-naïve or treatment-experienced to an IFN-based regimen and who have ESRD on HD.

NCT02806362 Chronic Hepatitis C Virus Drug: Ombitasvir/paritaprevir/ritonavir
MeSH:Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis Hepatitis, Chronic Kidney Diseases Kidney Failure, Chronic
HPO:Abnormality of the kidney Chronic active hepatitis Chronic hepatitis Hepatitis Nephropathy

Exclusion Criteria: - Presence of Y93H variant at Screening - Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human immunodeficiency virus antibody (HIV Ab) - Significant liver disease with any cause other than chronic HCV infection - On peritoneal dialysis - On hemodialysis for more than 15 years Inclusion Criteria: - Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile - Hepatitis C Virus (HCV) Ribonucleic acid (RNA) greater than 10,000 IU/mL at Screening - Chronic HCV, Genotype (GT)1b infection - Treatment-naive or treatment-experienced with an interferon (IFN)-containing regimen (IFN or pegylated-IFN with or without ribavirin). --- Y93H ---

Exclusion Criteria: - Presence of Y93H variant at Screening - Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human immunodeficiency virus antibody (HIV Ab) - Significant liver disease with any cause other than chronic HCV infection - On peritoneal dialysis - On hemodialysis for more than 15 years Chronic Hepatitis C Virus Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis Hepatitis, Chronic Kidney Diseases Kidney Failure, Chronic null --- Y93H ---

Primary Outcomes

Description: SVR12 defined as the hepatitis C virus (HCV) ribonucleic acid (RNA) level less than the lower limit of quantification (LLOQ) 12 weeks after the last dose of study drug.

Measure: Percentage of participants achieving a 12-week sustained virologic response (SVR12).

Time: 12 weeks after the last dose of study drug

Secondary Outcomes

Description: On-treatment virologic failure was defined as the following: Confirmed increase from nadir in HCV RNA (2 consecutive HCV RNA measurements greater than 1 log10 IU/mL above nadir) at any time point during treatment; or Confirmed HCV RNA greater than or equal to LLOQ after HCV RNA is less than LLOQ during treatment; or HCV RNA greater than or equal to LLOQ persistently during treatment with at least 6 weeks of treatment.

Measure: Percentage of participants with on-treatment virologic failure

Time: Up to Week 12

Description: Participants with a confirmed HCV RNA greater than or equal to the LLOQ between Final treatment visit and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA less than LLOQ at Final treatment visit.

Measure: Percentage of participants with relapse

Time: Up to 12 weeks after the last dose of study drug

5 Treatment Efficacy and Safety of 12 Weeks of Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without Baseline NS5A Resistance-associated Variants (DARING)

A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein (NS5A) resistance-associated variants. Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks will be prescribed.

NCT03004625 Hepatitis C Drug: daclatasvir Drug: asunaprevir Drug: Ribavirin
MeSH:Hepatitis C

The existence of baseline NS5A RAV "Lycine 31 (L31F/I/M)" or "Tyrosine93 (Y93H)", by using direct-sequencing with RAV of > 20%. --- L31F --- --- Y93H ---

Primary Outcomes

Description: SVR12 is defined as undetectable HCV RNA 12 weeks throughout 12 weeks of post-treatment follow-up peroid

Measure: To determine the treatment efficacy (SVR12) of 12 weeks of daclatasvir and asunaprevir plus ribavirin for HCV-1b patients without baseline RAVs

Time: 6 months (including 3 months of treatment and 3 months of post-treatment follow-up peroid

Secondary Outcomes

Measure: To evaluate the number of participants with treatment-related adverse events of 12 weeks of daclatasvir and asunaprevir plus ribavirin for HCV-1b patients without baseline RAVs.

Time: 3 months

6 Safety of Sofosbuvir Plus Daclatasvir in Patients With Chronic Hepatitis c Virus and Assessment of Resistance Associated Variants in Resistant and Relapsed Cases

To identify side effects of Sofosbuvir/ Daclatasvir treatment regimen of chronic HCV GT-4 infection. - To assess the occurrence and the prevalence of RAVs in patients with treatment failure and relapse after sofosbuvir and daclatasvir with assessment of their types . - To examine the GT4 subtypes by phylogenetic analysis and baseline sequence variability among subtypes and their potential impact on treatment outcome and development of viral resistance in patients who received a regimen of Sofosbuvir/ Daclatasvir for treatment of chronic HCV GT-4. - To assess the differences in patient demographics across GT4 subtypes.

NCT03572140 HCV Diagnostic Test: RAVS In relapsed and resistent cases

NS5A RAVs can be very common, with Y93H detected in up to 15% of the population and L31M in up to 6.3%. --- Y93H ---

Primary Outcomes

Description: that may be used in the future to predict the response to Sofosbuvir and this will save a huge cost for Egypt .

Measure: relevance of HC RAVs to the outcomes of therapy with Sofosbuvir in treatment of egyptian patients infected with HCV genotype 4

Time: baseline


HPO Nodes


HP:0000077: Abnormality of the kidney
Genes 1699
SMC1A MAGED2 NAA10 NUP133 AR COL1A1 IL17RC TCF4 CASR ARX SLC34A1 ALX4 TACR3 ZNF423 EXT2 NOD2 HNF1B CEP290 SETD5 COL4A3 FGF17 OCRL CHD7 HESX1 FOXP3 KCNJ11 CCDC141 PRKCD SOX10 SETBP1 MAFB SLC4A1 MAP2K1 ERAP1 IL17RA DNASE1L3 SMS TP53 TMEM70 KCTD1 PGK1 PRMT7 NDUFS1 NEK8 ALG9 CTRC RAP1B MEN1 PTPN11 EIF2AK3 EFEMP2 GLI2 WDR35 GNB1 SDCCAG8 CEP164 BSCL2 KNL1 HPRT1 LMNB2 WWOX CRB2 PROK2 SLC3A1 ND3 XRCC2 PC COX6B1 SGPL1 REST ANTXR1 EBP RPGRIP1L TMEM67 FCGR2B FGF10 FBLN5 TRNS1 SOX4 H19 PTEN PTPN11 RAB23 FLCN SERPINF2 MNX1 DHDDS SDHC GBA LDLRAP1 SSR4 ZIC2 BBS12 PIK3CA FBN1 USP9X FAM20C AGXT GCK MRPS22 B9D2 HLA-DPA1 PAX2 FLNA BBS1 FAM20A XDH STRA6 ACSL4 SOX17 CWC27 FOXF1 FN1 LIPN GP1BB CCDC22 CTNS SULT2B1 PROKR2 KCNE5 BRCA1 DVL3 POR STXBP1 RFWD3 NDUFS2 HRAS WDR19 ASXL1 CEP55 COL7A1 WDR73 TBX1 NUMA1 LIG4 ITGB3 FGFR1 ND5 SDHD PEX3 GPC3 MOCOS CAV1 RPGRIP1L ADAT3 STAT5B LMAN1 FGF20 SDHB PMM2 EXT2 SRY CCR6 APOL1 VHL DEAF1 MYLK LEMD3 MMUT SPINK5 CLCN5 NDUFS7 CFHR5 OGG1 NPHP1 VIPAS39 PIGA APOA1 SLC17A5 GLI3 KCNJ5 GPC3 NABP1 RARB PIEZO2 CIT UQCC2 SNRPB KLLN NSUN2 NBN WT1 PPP1R15B FAT4 PEX1 CLDN19 TBX18 FIBP DVL1 GREB1L TRNT MKKS THOC6 ZFP57 CEP63 MYH9 FGA KCNA1 CLCN5 SALL4 TRAF3IP2 OSGEP ITGA2 CEP290 PRODH SLC4A4 ND2 SLC2A2 LETM1 LPIN2 SMC3 IFT172 TBX1 COL4A5 H19 NDUFAF3 CAMKMT RBM10 SRCAP CHRM3 LHX1 EYA1 SRY UBE2T TACO1 TMEM67 F10 CEP290 SCN2A EPG5 INF2 ITPR3 WT1 RPS26 FUZ GREB1L FAH CC2D2A COX20 FANCE POU3F4 DHCR24 NPHP1 RBM10 SLC6A17 KEAP1 CHD7 OCLN DCDC2 EDNRB PTCH1 FGFR3 PIK3C2A GALNT3 SH2B1 SOX9 FGFR1 ARNT2 NOD2 TRIM32 SDHC TBC1D24 NDUFV1 AKT3 SEC23B SPRY4 KIF7 SIK1 GP9 KYNU CACNA1S HLA-B NOTCH2 GRIP1 DACT1 HNF1A BUB1B CEP120 C1QBP WT1 BRAF GAS1 MBTPS2 PLG EIF2AK3 SRC TXNL4A ENPP1 YY1AP1 GPC4 CAV1 DHCR7 ADA2 HNF1A CSPP1 BBS12 TRIP13 IL23R CPT2 FLNA NDUFS8 FLNA COG1 ND1 FANCA POU6F2 SIX5 TTC8 CD151 NSD2 SON FANCM LDLR RET VHL GCM2 RBM8A DZIP1L CTLA4 SOX9 ALOXE3 LIPT2 ADGRG2 HPRT1 SFTPC TRIP13 ZAP70 UBR1 DNASE1L3 DSTYK AKT1 HAAO ARL6 FLRT3 NXN RASGRP1 ATP1A1 PPP2R3C CILK1 CFTR ND5 NDUFB11 ARX HLA-B GTF2I DLC1 TMEM237 SON PTPN22 KCNJ11 CEP135 TREX1 BTNL2 TRAF3IP1 SLX4 KMT2D DKC1 APOE SCO1 TMEM231 PLG FREM2 DNA2 PGAP2 FANCI SLC34A1 TRAF3IP1 PDX1 LRP4 TTC8 IL17RD FIG4 PIK3CA SI GPC3 RET PEX16 CPT1A SLC2A9 OSGEP TRNE DSTYK DICER1 CTU2 HYLS1 FGFR2 ARX HNF4A ALG9 NUP107 TMEM231 HOGA1 CHN1 CLPB GDNF WDR34 SEMA3E TBC1D8B ARL6IP6 RERE LAGE3 WT1 BBS10 SRP54 ABCC8 DYNC2H1 ATRX GPC4 COQ8B SIX1 OFD1 B2M ACTB SCARB2 LEMD3 SPINK1 MUC1 SDHD DDX59 SLC36A2 GABRD PEX12 CTH IRAK1 CLCN5 MST1 PAX1 RAF1 VAMP7 RIPK4 WT1 APC TRIM28 SMARCA4 AKT1 RECQL4 G6PC3 FAM149B1 TP63 ARL3 CDKN1C FLNA GNAO1 FGF8 CFH ARID2 TDGF1 SNRPB FLNA DIS3L2 VPS33B PGK1 PGAP3 COL4A4 CTNS F8 TRNQ POLE PAX4 FGFR2 TRIM8 CC2D2A SLITRK6 COX8A PQBP1 WAS KDM6A FANCE GNB1 SDHD ANLN HLA-DRB1 SHH MKS1 SLC25A20 ALMS1 BRCA2 NRAS TSC1 TMEM67 MAP3K7 DMP1 SMC1A ARID1A FANCD2 DYNC2H1 NEK1 DDX59 VHL GLA CDC42 MAP11 PLCD1 FOXE1 ARMC5 SLC25A11 WDR73 PTPN22 DYNC2H1 STXBP1 RFWD3 ND1 HSD17B4 GRIA3 GATA4 KCNJ10 LRP5 GLA FANCL NUP133 FRAS1 ND6 PHGDH WDR73 FIBP NR5A1 FLT1 FN1 COMT WASHC5 BMPER CFB NAA10 MKKS WAS UMOD SOX10 UMPS CDC42 PIGY TRNS1 RAB3GAP2 NCAPD3 HPSE2 COX1 ALG8 ACTN4 REST ZBTB16 HS6ST1 MAFB MOCS2 SIX3 ND4 C1QA ZNF423 OPLAH MET FKRP NUP107 FANCB HMBS PTPN22 RAI1 C1QA ELN PEX19 PAX6 SLX4 CYP27A1 USF3 MMUT HMOX1 BUB3 H19-ICR NDUFA11 RYR1 FANCA AP2S1 DYNC2LI1 CCN2 RAI1 MASP1 TCTN2 CCR1 MAD2L2 FOXI1 TMEM237 MAGI2 SMARCC2 TRNV WASHC5 HMGA2 C8ORF37 COX14 CEP57 BMP4 MCM5 CLDN19 GSN WNT4 WIPF1 TMEM67 CLCNKB TRNN ZNF592 LMNA SCNN1B F5 BUB1 CTLA4 RARA SCNN1G TFE3 CPT1A GLMN SIX5 SLC25A22 HNF1B SF3B4 COL4A4 FLCN JAM3 MYO1E IFT140 EPAS1 SPECC1L CEP55 COQ6 PHYH KCNQ1OT1 BBS7 NDUFAF4 BBS2 CDKL5 MARS1 PIGT NPM1 BBS9 ABCC6 ALG1 SLC34A3 VHL PEX26 TCN2 INSR SLC12A3 PRDX1 WFS1 ETFDH CISD2 COA8 IFT27 OSTM1 IL6 LIMK1 FIP1L1 TBL2 PAX2 CLDN16 WDR19 CEP164 PNPLA6 TRNT1 SDR9C7 ARL6 NADK2 TGIF1 WDR4 TBL1XR1 NPHP1 INPP5E SLC26A1 ENPP1 MDH2 STRA6 YY1 FBXL4 AFF4 KIAA0586 ASPM FKTN ADAMTSL1 TP53 KRT17 SLC1A1 OFD1 TMCO1 XPNPEP3 HIRA PRKCSH PEX7 BBS10 CCBE1 C3 MCPH1 NEK8 RAD21 NDUFAF3 DPF2 KMT2D SEC63 ADAMTS13 BUB1B CHD4 PIGO ANTXR1 FANCF WDR19 DACT1 CEP152 TBC1D20 PLVAP FAS SIX1 CTNS BMPER SLC30A9 HLA-DPB1 SDCCAG8 DLST PGM3 KANK2 GNA11 ADA TMEM138 SLC35A2 LDHA EYA1 CFI ITGB4 NDUFAF5 COQ7 KCNJ11 C1QC HNF1B TP63 WDR19 PBX1 TMEM216 CC2D2A LMX1B TTC21B ITGA3 RPGRIP1L FAT4 COQ2 HNRNPU RAI1 TRNL1 KIAA0753 CASP10 PRKCSH COL3A1 CHST14 TRIP11 BRF1 SDHB SLC7A7 CYTB SLC3A1 CDH23 CYP4F22 IQSEC2 SAA1 CDC73 ATRX ALOX12B GDF2 ALMS1 GBA PUS3 PIGV TSC2 CASR WT1 SALL4 PUF60 NPHP4 DYNC2LI1 TRIM28 SLC34A1 SNAP29 RAD51C CDC73 PIGL RRM2B PIK3CA FH HNF4A BCOR SMARCAL1 IFT172 MYD88 PDE6D JAG1 IKZF1 PYGM DICER1 NUP107 DMRT3 WNT3 HNF4A BBS4 ZEB2 TNXB PRPS1 MLXIPL LMNA ALDOB PGAM2 KCNQ1OT1 POGZ PACS1 CAVIN1 GCM2 PPARG ELP1 BAZ1B MAX TPRKB PEX1 NDUFV2 ABCC6 GATA3 IARS1 WDPCP ACTG1 SPP1 GANAB CCND1 SDHB TMEM138 RET SDHA MBTPS2 NR0B1 CFH FOXP1 FLNA WT1 NIPBL PTPRJ MECP2 NDUFA1 GTF2IRD1 CREBBP IFIH1 ETFB LAMB2 GP1BA THBD PHYH OCRL CSPP1 IL2RG PORCN CLDN10 MYO5B SOX11 PEX1 KCTD1 KYNU B9D1 TCTN3 NUP133 KCNJ10 MAP2K2 TTC37 CFI SPART CHD7 PIK3CA BRAF NDUFAF3 CLEC7A KIF14 VPS33A COPB2 TRNL1 BAP1 NRIP1 PIEZO2 DSE ADCY10 CCND2 LMOD1 DPH1 GLIS3 CFI CHST14 TRNK TBX1 FLNB PEX11B ND1 ELP1 SETD2 INS HBB AIP CLCNKB COX2 FASTKD2 EYA1 FGFR3 SCNN1B UMOD HABP2 CORIN ALG8 MYH11 FAN1 PPP3CA H19 RMRP PLCE1 PLCD1 CDKN1B NPHP4 ACTG2 VHL DCC SLC6A19 KIF14 REN RPGRIP1L WDR60 ACTG2 RPGRIP1 LMX1B NDUFB8 NSD1 FLCN H19 TMEM126B MEFV MAPKBP1 NCAPG2 INPP5E PIGN CCBE1 TMEM216 HMGA2 CA2 PIK3R2 KANSL1 MITF FREM1 STAT3 CENPF PCK1 APRT SEC24C TSC1 GLI3 CRB2 C1R HPSE2 B3GLCT NF1 POMT1 TAF13 ADAMTS3 PIGN ZFPM2 HLA-DRB1 TRRAP FREM1 MAP3K1 WDR62 TMEM67 FANCC AVPR2 IFT122 SDHB TMEM107 BBIP1 WDR4 LMNA ACVRL1 DIS3L2 PIGA COL5A2 B4GAT1 MKKS MED25 APC BCOR LTBP4 APOE MTRR ERCC4 MME EMP2 LRP2 BCS1L SDHD IFT140 SDCCAG8 MMACHC DISP1 PEX5 IFT80 GLI1 HPS1 DNASE1 LARGE1 ELN TFAP2A PTEN WNT5A AVPR2 CPT2 TREX1 PIGP PEX10 NPHP1 CHRM3 AXIN2 HNF1A SALL4 MMUT TELO2 DCC KIF1B CASK PHEX RREB1 RPGRIP1L IGF2 WDPCP FANCC PEX13 CD46 PGM3 WT1 KLLN PEX2 POMT2 BICC1 NSDHL G6PC AMMECR1 DLL1 WRN AQP2 SARS2 SOX9 SBDS GP1BB PAX2 CA2 VDR DIS3L2 RAD51C NDUFAF1 NPHS2 MAX TMEM231 PALB2 UBR1 PRTN3 MSH2 RECQL4 MEFV PIGL ITGA6 ATP7B USP8 H19 LCAT GRHPR C3 XYLT1 TTC21B HOXD13 CD109 DICER1 CEL KYNU FRAS1 TRNF APRT TBX15 TMEM107 NDUFA6 APOB MITF RAB18 PRDM16 CEP41 FLI1 STAT3 BNC2 INF2 SKI COPA PIK3R2 DHODH IFT43 PKHD1 CC2D2A PPP2R1A PRKAR1A IQCB1 GLI3 CD96 KDM6A KCNJ10 ATRX SCO2 DGKE FGFR2 USP8 ND4 PEX6 SLC29A3 KIF1B MFSD2A PML PPM1B VHL AQP2 PCK2 SLC12A1 SLC3A1 WNT4 SMARCAL1 KITLG SC5D BBS4 RERE NDUFS4 MSH3 ABCC6 SLC4A1 SLC22A12 INTU GSN FANCL PDX1 SDHB PEX14 ATRX PIGW CRTAP B9D1 CASR INSL3 INVS NDUFS6 RAP1A WDR11 CLIP2 ERCC8 PEX5 HSD11B2 NPHP3 MKKS COL4A1 TMEM127 ANOS1 MEOX1 CDK5RAP2 FANCI CEP290 TIMMDC1 TMEM127 GPKOW SHH FOXH1 ALDOB TMEM260 CEP120 TBC1D24 MAP3K7 UBAC2 NLRP3 NOTCH2 TSC2 YAP1 TMEM67 ADA RAG2 WDR35 PRSS1 KCNQ1 PEX7 CEP290 WDR60 FLNA NTNG1 ROR2 SEC61A1 F2 POU6F2 BCOR CDK6 CASR ATN1 RET TMEM231 PIGV NOTCH2 CPLANE1 SF3B4 PDSS2 AMMECR1 TRIM32 SDHAF2 SLC26A4 APC ITGB4 GNAS ATP6V0A4 ANOS1 USP9X PIGN PREPL FANCD2 CYP24A1 BBIP1 ITGA8 CPLANE1 BRCA2 KCNJ1 SEMA3A PAFAH1B1 TPRKB MGME1 TRNW RPL11 RNU4ATAC SLC37A4 BCS1L ARID1B APC2 KMT2A TRNH DNAJB11 CLCNKA RNU4ATAC RPS19 GPR35 TBX1 GDF6 ATP6 TFAP2A PRKCD PIGT TBX3 NPHP1 NUBPL TCTN3 SCARB2 AKT1 NLRP3 KAT6A B9D2 PTCH1 IL17F NPHP3 CDC73 H19 NFIA IRF5 FAS NPHP4 LRP4 DPH1 ATP6V1B1 COL4A3 RBBP8 BBS5 PDSS2 VAC14 NPHP3 MDM2 KLF11 AGTR1 WDR19 CEP290 GABBR2 CPT2 FREM2 AGXT C8ORF37 TSC1 AGPAT2 RNF139 MEFV PEX13 ESCO2 AMMECR1 COQ2 YWHAE APPL1 SCNN1A STIL CPT2 PEX6 CCDC141 DCLRE1C PREPL EVC2 FXYD2 BSCL2 FEZF1 LYZ SLC6A20 XRCC4 NUP85 IL12A FASLG RSPO2 ERCC6 SASS6 CLCNKB FOXF1 STOX1 PTPRO BUB1 ENG CTNNB1 HSPA9 PKD2 COG7 THOC6 TRNL1 HOGA1 STS FGFR3 IL12A-AS1 WFS1 NELFA LMNB2 GPC4 SUFU TRIP13 AMER1 COX10 HDAC8 PEX2 CFH KISS1R SETBP1 KIAA0753 KMT2A PEX3 NEUROD2 CSPP1 WDR19 KRAS DCHS1 NIPAL4 MOCS1 UFD1 GPC3 FLNB B3GLCT C4A FGFR1 HGD TMEM216 DNAJC21 ITGA2B YAP1 FOS SERPINH1 BRCA2 HELLPAR CACNA1D FGFR3 JMJD1C HOXA13 CD46 IFNG PALB2 FAT4 FCGR2A ITGA2B ND3 TBCK KRAS GLIS2 HPRT1 FUT8 RAD21 RMND1 NSD1 NDUFS2 RTTN CDK4 RAD51 PHC1 CD2AP PIGL NUP205 PEX19 PORCN SEMA3E PIGQ ZIC3 PROKR2 HYMAI SERPINA1 NPHP3 FGF8 TP53RK SMOC1 EVC LRP5 SMARCB1 CCND1 OCRL ABCG8 PLD1 WDR34 SPECC1L FLCN ERCC4 MKS1 IRF2BP2 STAT4 CTNNB1 MAFB STK11 LEMD3 ETFA ND2 ABCA12 ACP5 MYMK STRADA RPL26 WNT4 TTC21B CDKN1C ROBO2 PRCC TMEM231 ABCC8 AGGF1 RAG1 ANKS6 LRIG2 SDCCAG8 CDKN1B ALPL TRIM37 ADCY10 FANCB ABCC8 SMARCE1 LMX1B DYNC2LI1 NDUFAF2 LMX1B CDC73 MEFV CACNA1D NDUFB9 ITGA8 MSH6 FOXRED1 AHI1 TAPT1 STXBP1 TMEM216 PDE6D RFC2 ERBB3 HNF4A STRADA PUF60 ZIC3 CCNQ ND6 PET100 EP300 XYLT2 SOX18 GNA11 TRNW DLL4 NODAL CENPJ TBX22 MBTPS2 MICOS13 SC5D PMM2 PAH CIT FOXC2 IQCB1 KLRC4 PLAGL1 PEX10 KCNAB2 CHD7 BRAF AGPAT2 LPIN1 HBB ENPP1 SF3B4 ARID1B PIGY FGFR2 LZTFL1 COLEC11 ACE INS SHANK3 SLC37A4 MCFD2 FH CEP290 SLC9A3R1 GATA3 SHPK EP300 TMEM67 WNT3 OFD1 CAD IL7R FGFR2 NDUFS3 ESCO2 TKT GDF6 COL14A1 APC SLC5A2 WT1 DZIP1L SLC7A9 DUSP6 RAI1 AFF4 LIG4 SURF1 CEP83 GDF3 LAGE3 KCNH1 ITGB3 SPRY2 SHANK3 BBS1 STAG1 CYP11B2 NPHP1 WT1 BRIP1 WT1 ALDH18A1 IGF2 NIPBL AGT TMEM126B CLCN5 TALDO1 ARHGDIA NUP160 DHCR7 BUB1B IFT172 HIC1 CD81 GCK HSPG2 UMOD EHMT1 SMAD4 STAT1 TTC37 NPHS1 C4A PEX12 POR INVS MINPP1 PTPN22 TRNK ATP7A TRPC6 TTR OFD1 WNT4 EHMT1 IGF2 NARS2 MKS1 FLII TMEM237 PKD1 CC2D2A PKHD1 NSMF HNF1B SKIV2L MED25 SLC12A3 TCTN2 GBE1 CCDC28B SCN1B ANKLE2 TLR4 IFT27 PIK3CA RBM8A FANCB NDUFB10 MCTP2 CCND1 IL10 NOTCH3 TSC2 COA8 BSND GEMIN4 CASP10 KIF14 TCTN3 ZNF148 STAT4 NPHS1 PLEC ARVCF ZNF687 ROR2 COX3 ZAP70 PDGFRB POLR3A CDKL5 COL4A1 CCNQ TNXB COL5A1 TREX1 FH COG6 LZTFL1 SLC7A7 CFHR1 NUP93 PUF60 LRIG2 COL4A3 FAM20A AIRE GRHPR TRNS2 HRAS HDAC4 FANCG WDR35 KLHL7 CFHR3 TGM1 PYCR2 NLRP3 C1QB FLCN BLK NRAS CYB561 IFT80 AAGAB REN NEUROD1 PHF21A RAB3GAP1 MLH1 FANCB WDR34 EXTL3 GP1BB KAT6B TMEM216 IGF2 NPHP3 STX3 DCHS1 PTH1R HPRT1 SALL1 KAT6B LAMB2 GP1BA PNKP IFT43 NDUFB3 PCSK9 FAS SALL1 TP53RK VPS33A CDON CD96 ABCG5 SNAI2 VANGL1
Protein Mutations 4
C282T C677T K55R Y93H
HP:0000083: Renal insufficiency
Genes 446
OCRL CSPP1 CLDN10 COQ8B SIX1 KCTD1 SCNN1A CPT2 TCF4 CFI FXYD2 BSCL2 MUC1 HNF1B NUP85 IL12A FASLG ERCC6 TRNL1 STOX1 SETD5 OCRL PKD2 IRAK1 CLCN5 MST1 TRNL1 STS IL12A-AS1 ERAP1 CFI DNASE1L3 HDAC8 WT1 CFH ND1 PGK1 KMT2A WDR19 NEK8 COX2 NIPAL4 MEN1 EIF2AK3 SCNN1B UMOD SDCCAG8 CORIN CFH HPRT1 FAN1 XRCC2 FOS PGK1 PLCE1 COL4A4 HELLPAR NPHP4 TRNQ REN SGPL1 HOXA13 CD46 PALB2 CC2D2A RPGRIP1L GLIS2 TMEM126B TMEM67 MEFV FANCE MAPKBP1 INPP5E RMND1 TMEM216 ANLN HLA-DRB1 TRNS1 RAD51 ALMS1 TSC1 CD2AP TMEM67 NUP205 APRT DHDDS CRB2 SMC1A C1R HPSE2 NPHP3 TP53RK FANCD2 HLA-DRB1 GLA OCRL TMEM67 AVPR2 IFT122 WDR73 ERCC4 DYNC2H1 AGXT HLA-DPA1 STAT4 PAX2 GLA MAFB NUP133 FAM20A LEMD3 APOE ABCA12 FLT1 FN1 ACSL4 ERCC4 MME FN1 CFB LIPN UMOD IFT140 MMACHC TTC21B CTNS SULT2B1 KCNE5 BRCA1 IFT80 RFWD3 COX1 HPS1 WDR19 ELN COL7A1 WDR73 ACTN4 ND5 CPT2 ND4 ANKS6 LRIG2 MOCOS NPHP1 ZNF423 NUP107 HMBS CAV1 PTPN22 RPGRIP1L MMUT C1QA ELN PAX6 MMUT LMX1B RYR1 RPGRIP1L AP2S1 CCR6 CCN2 LMX1B FANCC APOL1 MEFV CD46 CCR1 MAD2L2 TMEM237 BICC1 MAGI2 MMUT AMMECR1 CLCN5 AHI1 CFHR5 SARS2 PAX2 RFC2 RAD51C CLDN19 GSN NPHS2 CLCNKB ZNF592 SCNN1B CCNQ WT1 TBX18 ND6 CTLA4 PRTN3 SCNN1G TRNT MEFV LCAT SIX5 GRHPR C3 XYLT1 HNF1B TTC21B XYLT2 MYH9 SOX18 KYNU MYO1E TRNF IFT140 APRT CLCN5 BNC2 SMC3 IQCB1 KLRC4 IFT172 COL4A5 TCN2 PKHD1 AGPAT2 LPIN1 HBB CC2D2A PRDX1 IQCB1 IFT27 LIMK1 CHRM3 LHX1 DGKE TBL2 PAX2 UBE2T CLDN16 WDR19 CEP164 PNPLA6 SDR9C7 CEP290 TMEM67 GATA3 AQP2 NPHP1 SLC26A1 CEP290 SHPK SMARCAL1 INF2 KIAA0586 FUZ FAH SLC22A12 GSN FANCL NPHP1 OCLN OFD1 DCDC2 DZIP1L XPNPEP3 SLC7A9 BBS10 CEP83 SH2B1 LAGE3 C3 SPRY2 INVS RAD21 NPHP1 NOD2 CLIP2 ERCC8 BRIP1 WT1 HSD11B2 CHD4 NPHP3 NIPBL FANCF COL4A1 CLCN5 FAS ARHGDIA CACNA1S HLA-B NUP160 CTNS IFT172 DACT1 SLC30A9 HLA-DPB1 SDCCAG8 CEP120 WT1 UMOD EHMT1 TMEM138 EIF2AK3 LDHA EYA1 CFI ALDOB TMEM260 C4A CAV1 UBAC2 INVS PTPN22 TRNK TMEM67 TRPC6 WDR19 PBX1 IL23R CPT2 LMX1B TTC21B WDR35 ITGA3 PEX7 CEP290 COG1 WDR60 FANCA SIX5 CD151 TMEM237 SEC61A1 PKD1 CC2D2A PKHD1 HNF1B FANCM TMEM231 NOTCH2 DZIP1L SLC7A7 TLR4 SLC3A1 CYP4F22 ALOXE3 AMMECR1 SAA1 CDC73 HPRT1 IL10 ALOX12B DSTYK ALMS1 PUS3 RASGRP1 TSC2 BSND BBIP1 CASP10 BRCA2 NPHP4 DYNC2LI1 STAT4 TPRKB NPHS1 RAD51C HLA-B CDC73 GTF2I TRNW COX3 SLC37A4 COL4A1 HNF4A MYD88 JAG1 BTNL2 TRAF3IP1 SLX4 TRNH IKZF1 PYGM DNAJB11 LZTFL1 NUP107 CLCNKA CFHR1 NUP93 GPR35 PRKCD LRIG2 COL4A3 FAM20A GRHPR TRNS2 PRPS1 MLXIPL HRAS NPHP1 FANCG FANCI SLC34A1 TRAF3IP1 SCARB2 CFHR3 TGM1 NLRP3 PGAM2 CAVIN1 GCM2 PPARG ELP1 BAZ1B NPHP3 CDC73 IRF5 FAS NPHP4 ABCC6 GATA3 FANCB WDR34 COL4A3 SPP1 OSGEP NPHP3 TRNE CCND1 HPRT1 SALL1 LAMB2 IFT43 FAS WDR19 CFH SALL1 CEP290 TMEM231 CLPB CPT2 WT1 AGXT TBC1D8B GTF2IRD1 VANGL1 LAMB2 THBD PHYH
Protein Mutations 2
L31F Y93H
SNP 0